Literature DB >> 8319378

The possible role of stromal cell stimulation in worsening the prognosis of a subset of patients with breast cancer.

T H Stewart1, S C Tsai.   

Abstract

This review examines the evidence that a subset of patients with breast cancer have tumors that are stimulated to grow by host cells in the tumor stroma. The search for such a minority group was prompted by the following observations. Adjuvant chemotherapy which is immunosuppressive improves disease-free interval and survival, whereas non-specific immunostimulation worsens the prognosis. Intrinsic immune reactivity is associated with a poor prognosis. A subset of tumors with a bad prognosis has anaplastic cells, dermal lymphatic invasion and a moderate to intense lymphoplasmacytic stromal infiltrate. Evidence is reviewed that adjuvant chemotherapy may be beneficial by virtue of its immunosuppressive effects in addition to tumor kill of minimal residual disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8319378     DOI: 10.1007/bf00058049

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  43 in total

1.  V. A Study of Carcinoma Mastitoides.

Authors:  E A Schumann
Journal:  Ann Surg       Date:  1911-07       Impact factor: 12.969

2.  LIFE EXPECTANCY FOLLOWING RADICAL AMPUTATION FOR CARCINOMA OF THE BREAST: A CLINICAL AND PATHOLOGIC STUDY OF 218 CASES.

Authors:  W E Sistrunk; W C Maccarty
Journal:  Ann Surg       Date:  1922-01       Impact factor: 12.969

3.  Some international differences in histology and survival in breast cancer.

Authors:  A S Morrison; M M Black; C R Lowe; B MacMahon; S Yuasa
Journal:  Int J Cancer       Date:  1973-03-15       Impact factor: 7.396

4.  Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells.

Authors:  S Nakamura; S Z Salahuddin; P Biberfeld; B Ensoli; P D Markham; F Wong-Staal; R C Gallo
Journal:  Science       Date:  1988-10-21       Impact factor: 47.728

5.  Host resistance and survival in carcinoma of breast: a study of 104 cases of medullary carcinoma in a series of 1,411 cases of breast cancer followed for 20 years.

Authors:  H J Bloom; W W Richardson; J R Field
Journal:  Br Med J       Date:  1970-07-25

6.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1992-01-11       Impact factor: 79.321

7.  Advanced stage and early relapse of breast carcinomas associated with high thymidine labeling indices.

Authors:  J S Meyer; B Hixon
Journal:  Cancer Res       Date:  1979-10       Impact factor: 12.701

8.  'Macrophages' and their putative significance in human breast cancer.

Authors:  J P van Netten; B J Ashmed; D Cavers; C Fletcher; I G Thornton; B L Antonsen; P Coy; M L Brigden
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

9.  Possible host resistance in carcinoma of the breast: a histological study.

Authors:  I M Hamlin
Journal:  Br J Cancer       Date:  1968-09       Impact factor: 7.640

10.  Histology in breast cancer prognosis.

Authors:  H R Champion; I W Wallace; R J Prescott
Journal:  Br J Cancer       Date:  1972-04       Impact factor: 7.640

View more
  10 in total

1.  Association between breast cancer and autoimmune thyroid disorders: no increase of lymphocytic infiltrates in breast malignant tissues.

Authors:  P Fierabracci; A Pinchera; D Campani; L E Pollina; E Giustarini; C Giani
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

Review 2.  Are cellular adhesion molecules involved in the metastasis of breast cancer?

Authors:  M Maemura; R B Dickson
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 3.  Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.

Authors:  T L Whiteside; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

Review 4.  The tumor microenvironment and its role in promoting tumor growth.

Authors:  T L Whiteside
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

5.  MHC class I antigens and tumour-infiltrating leucocytes in laryngeal cancer: long-term follow-up.

Authors:  F Esteban; M Redondo; M Delgado; F Garrido; F Ruiz-Cabello
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

6.  Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells.

Authors:  G B Ragnarsson; E K Mikaelsdottir; H Vidarsson; J G Jónasson; K Olafsdóttir; K Kristjánsdóttir; J Kjartansson; H M Ogmundsdóttir; T Rafnar
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

Review 7.  Complement anaphylatoxins as immune regulators in cancer.

Authors:  Eli T Sayegh; Orin Bloch; Andrew T Parsa
Journal:  Cancer Med       Date:  2014-04-08       Impact factor: 4.452

8.  The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer.

Authors:  A M Al Murri; M Hilmy; J Bell; C Wilson; A-M McNicol; A Lannigan; J C Doughty; D C McMillan
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

9.  Bladder carcinomas and normal urothelium universally express gp200-MR6, a molecule functionally associated with the interleukin 4 receptor (CD 124).

Authors:  M F Tungekar; K C Gatter; M A Ritter
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

10.  Computational image features of immune architecture is associated with clinical benefit and survival in gynecological cancers across treatment modalities.

Authors:  Sepideh Azarianpour; Germán Corredor; Kaustav Bera; Patrick Leo; Pingfu Fu; Paula Toro; Amy Joehlin-Price; Mojgan Mokhtari; Haider Mahdi; Anant Madabhushi
Journal:  J Immunother Cancer       Date:  2022-02       Impact factor: 12.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.